StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Palvella Therapeutics's ebitda for the twelve months ending Sep 30, 2024 was $3.43M. For fiscal 2023 it was -$9.97M.

Annual ebitda

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$9.97M–
FY2022Dec 31, 2022-$40.70M–
FY2021Dec 31, 2021-$49.37M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2024Sep 30, 2024-$5.06M–
Q2 FY2024Jun 30, 2024-$2.91M-203.1%
Q1 FY2024Mar 31, 2024-$1.79M–
Q4 FY2023Dec 31, 2023$13.19M–
Q3 FY2023Sep 30, 2023-$11.07M–
Q2 FY2023Jun 30, 2023$2.82M–
Q1 FY2023Mar 31, 2023-$14.91M–
Q4 FY2022Dec 31, 2022-$10.94M–
Q3 FY2022Sep 30, 2022-$11.40M–
Q2 FY2022Jun 30, 2022-$11.75M–
Q1 FY2022Mar 31, 2022-$6.61M–
Q4 FY2021Dec 31, 2021-$10.39M–

More Palvella Therapeutics figures

See a number that looks wrong?